10112513Preclinical validation of evolution-designed, AI-discovered, synthetically printed biologic molecules for Chronic and MDR Lower Respiratory Tract InfectionsClosedCollaborative R&DInnovate UKAMPLY Discovery, using its proprietary AI-based technology platform, has established a pipeline of new, naturally occurring bioactive molecules designed to target complex bacterial infections. AMPLY's drug candidates show strong in vitro efficacy and excellent toxicity and bioavailability profiles. This project is focused on the preclinical validation of best-in-class lead candidates as an effective treatment alternative for chronic and multi-drug resistant bacterial lower respiratory tract infections, particularly chronic infections in Cystic Fibrosis (CF) patients.